BioNotebook: Aerie, Dynavax, Tetraphase, MEI Pharma, Sorrento, Can-Fite

Aerie prices $67.2m IPO; Dynavax sells $132.2m in stock, debt; Tetraphase plans $40m offering; MEI prices $35m offering; Sorrento joins Nasdaq, raises $30m; and Can-Fite garners $6m in Tel Aviv.

Aerie prices $67.2m IPO; Dynavax sells $132.2m in stock, debt; Tetraphase plans $40m offering; MEI prices $35m offering; Sorrento joins Nasdaq, raises $30m; and Can-Fite garners $6m in Tel Aviv.

Aerie garners $67m from IPO priced below

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas